Navigation Links
Diabetes Alliance to Feature 17 Presentations for Linagliptin and Investigational Compound Empagliflozin^ During the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD)
Date:9/17/2013

li>

Thursday, September 26, 1:45 – 2:45 CET, General Poster Session

  • Safety and Tolerability of Linagliptin in 7400 Patients with Type 2 Diabetes: A Pooled Comprehensive Analysis of Prospective Safety Reporting in Placebo-Controlled Studies (Presenting Author: M. Lehrke) [Poster No. 986]
  • Renal Safety of Linagliptin in Elderly Patients with Type 2 Diabetes: Analysis of Pooled Patient Data From 7 Phase 3 Clinical Trials (Presenting Author: A. H. Barnett) [Poster No. 926]

Linagliptin, which is marketed as TRADJENTA® (linagliptin) tablets in the U.S., is a once-daily 5-mg tablet used along with diet and exercise to improve glycemic control in adults with type 2 diabetes. Linagliptin should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis (increased ketones in the blood or urine). TRADJENTA has not been studied in patients with a history of pancreatitis, and it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using TRADJENTA.

What are TRADJENTA tablets? 
TRADJENTA is a prescription medicine that is used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.

TRADJENTA is not for people with type 1 diabetes or for people with diabetic ketoacidosis (increased ketones in the blood or urine).

If you have had inflammation of the pancreas (pancreatitis) in the past, it is not known if you have a higher chance of getting pancreatitis while you take TRADJENTA.

Important Safety Information

What is the most important information I should know about TRADJENTA?  
Serious side effects can happen to people taking TRADJENTA, including inflammation of the pancreas (pancreatitis), which may be severe and lead to death. Before you start taking TRADJE
'/>"/>

SOURCE Eli Lilly and Company; Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
2. Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community
3. Islet Sciences Announces Exclusive License Agreement with Yale University to Commercialize an Early Beta Cell Destruction and Diabetes Diagnostic
4. CASiGEN Pharma Receives A World-wide Exclusive License From GIBH To Bring New Potential Diabetes Treatments To The Global Market
5. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
6. Valeritas Inc. Selects dLifes New Diabetes Patient Engagement Solution For Valeritas V-go Disposable Insulin Delivery Device
7. Jentadueto® (linagliptin/metformin hydrochloride) tablets recommended for approval in the treatment of adults with type 2 diabetes in Europe
8. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
9. JDRF and BD Collaborate to Develop More Accurate and Reliable Glucose Monitoring Devices for People with Type 1 Diabetes
10. Eleven Integrated Health Systems Form Largest Private-Sector Diabetes Registry in United States
11. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... HILL, N.C. , Aug. 1, 2014  With ... is learning to speak a second language. Clinical efficacy ... new agencies established under the ACA like PCORI are ... With a variety of new entities and environments, the ... to speak the new language of outcomes and managed ...
(Date:8/1/2014)... -- In the latest call for gender equity in ... 60 doctors and leading medical experts from across the ... and Drug Administration,s (FDA) decision to approve 26 drugs ... dysfunction compared with ZERO for women,s most common complaint, ... by approving the first-ever drug to treat Hypoactive Sexual ...
(Date:8/1/2014)... 2014 According to the ... Closure, Anti infective), Basic (Films, Cleansing), Advanced (Hydrogels, ... Substitutes), Pressure Relief Devices, NPWT) - Global Forecast ... Market is expected to reach $18.3 Billion by ... a CAGR of 3.2% from 2014 to 2019. ...
Breaking Medicine Technology:Pharmaceuticals Learning the Language of the New Healthcare Landscape 2Pharmaceuticals Learning the Language of the New Healthcare Landscape 360+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 260+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 3Wound Care Market Worth $18.3 Billion by 2019 2Wound Care Market Worth $18.3 Billion by 2019 3
... to Four Years of Treatment Presented at ICAAC/IDSA,2008 ... (NYSE: SGP ) today reported a data ... demonstrated,sustained viral suppression and increased CD4 cell counts ... of therapy in treatment-experienced,HIV-infected patients. Vicriviroc was administered ...
... Pharmaceuticals, Inc. today,announced positive Phase 2 data for ... (AMC). The Phase 2 study compared,safety and efficacy ... 0796 to,Zyvox(R) in the treatment of patients with ... met its primary safety and,tolerability endpoint, demonstrating no ...
Cached Medicine Technology:Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 2Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 3Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 4Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 5Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 6Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 3Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 4
(Date:8/1/2014)... 01, 2014 The evolving healthcare ... community pharmacies. At ThoughtSpot 2014, AmerisourceBergen and Good ... practices and resources to enhance patient care and ... on critical issues to give independent pharmacists the ... , ThoughtSpot show attendance experienced a nearly ...
(Date:8/1/2014)... 1, 2014Lesbian, gay, bisexual, and transgender individuals who want ... as some of their heterosexual and cisgendered peers, such ... additional physiological and legal challenges to become parents. ... assisted reproduction options is presented in the article " ... published in LGBT Health , a ...
(Date:8/1/2014)... August 01, 2014 The American ... Gregg Harper (R-MS), and Peter Welch (D-VT), for ... Medicare Telehealth Parity Act of 2014, which improves ... this effort to improve healthcare access and affordability ... officer of ATA. "These cost-saving provisions are critical ...
(Date:8/1/2014)... 01, 2014 Market Publishers Ltd ... have been added to its catalogue. , ... Ingredients (APIs), Contract Research and Manufacturing Services (CRAMS), ... industry drivers include, among others, increasing ageing population, ... In 2015, the pharma market in India is ...
(Date:8/1/2014)... BEACH, FL (PRWEB) August 01, 2014 ... the 2014 California NextGen User Symposium in San Francisco, ... was held at the JW Marriott Union Square hotel. ... help practices get up to speed with ACA compliance ... earlier this month. The symposium provides attendees guidance with ...
Breaking Medicine News(10 mins):Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:Advances in assisted reproduction create more options and new legal issues for LGBT couples 2Health News:ATA Applauds Bill on Medicare Telemedicine Improvements 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 3Health News:Quirk Healthcare Foundation Hosts Fifth Annual California NextGen User Symposium and Launches First Annual Florida NextGen User Symposium 2
... the supermarket as well as the drugs cupboard when it ... published in the October issue of IJCP, the International Journal ... ask their doctors whether they should apply honey to their ... is one of the oldest foods in existence and was ...
... (ANSA) Organizes Artists Sign-On Letter as Part of Center for Health ... ... ANGELES, Oct. 17 Last week, 39 celebrity activists,and Artists for a ... improve the President,s Emergency Plan for AIDS Relief,(PEPFAR). PEPFAR currently restricts 1/3 ...
... Hall,founder of The Hall Center in Santa Monica, CA, ... of her patients. It wasn,t until she became,immersed in ... investigating her birth control patients more carefully.,"I was shocked ... patients on the,pill, had hormone levels that were on ...
... DUBLIN, Calif., Oct. 17 SuperGen Inc.,(Nasdaq: ... discovery, rapid,development and commercialization of therapies for solid ... have,been accepted for poster presentations at the AACR-NCI-EORTC ... in San Francisco. The poster presentations will ...
... Bulletin Board: HFIT), a leading employee health improvement company,will ... 30,2007, on Monday, November 5, 2007, after the market ... conference call to discuss the results the,same day. Participating ... and,Chief Executive Officer, and Wes Winnekins, Chief Financial Officer. ...
... IRIDEX,Corporation (Nasdaq: IRIX ) announced today that ... Executive Officer, and as a member of,the Board of ... of,Directors has appointed Theodore A. Boutacoff, who is currently ... serve as the Company,s President,and Chief Executive Officer. Prior ...
Cached Medicine News:Health News:Patients should ask surgeons about using honey to heal wounds 2Health News:39 Noted Performing Artists Urge Congress to Fix Flaws in President's Global AIDS Plan 2Health News:Do Not Take the Pill! Dr. Prudence Hall Tells her Teen and Female Patients 2Health News:Do Not Take the Pill! Dr. Prudence Hall Tells her Teen and Female Patients 3Health News:SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference 2Health News:SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference 3Health News:Health Fitness Corp. to Report Third Quarter 2007 Financial Results on November 5, 2007 2
... can be difficult for persons who have ... cord injuries and for children with poor ... other motor or coordination problems. The FoamWrap ... and coordination. Soft foam-lined material provides light ...
... a low profile contour at the palmar crease ... is an excellent choice to treat mild to ... or for wear following cast removal. The ... pile cinch fasteners provides support and compression to ...
... to treat DeQuervain's Tendonitis, strains and sprains ... advanced carpal tunnel syndrome and cumulative trauma ... Distal palmar crease contour allows for 90 ... Constructed from an open cell urethane ...
... is a solid, one-piece custom wrist orthotic designed to ... , ,Indications: , Wrist reconstruction , ... , Coles fracture - distal radius , ... , ORIF - Open reduction and internal ...
Medicine Products: